The Cameron InstitutePresident Trump recently asked CEOs of major research-based pharmaceutical manufacturers to increase research and development of new medicines, and add jobs in America. Given the fact that more is already spent on pharmaceutical research and development (R&D) in the United States than anywhere else in the world, this presents a serious challenge for pharmaceutical companies.
When you consider the fact that other countries benefit from the R&D money spent in the U.S. and as a result are able to spend far less on their own R&D, it begs the question: “Is this fair?”
Read the rest of this article on Independent Journal Review’s website
